# Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

> **NCT04317040** · PHASE3 · COMPLETED · sponsor: **Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 234 (actual)

## Conditions studied

- Coronavirus Disease 2019 (COVID-19)

## Interventions

- **DRUG:** Efprezimod alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04317040
- **Lead sponsor:** Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-24
- **Primary completion:** 2020-10-20
- **Final completion:** 2020-10-20
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04317040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04317040, "Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04317040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*